Delphia (USA)’s Biogen BIIB Stock Holding History

Delphia (USA)’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,270	Closed	-$339K	–	289
2022 Q3	$339K	Sell	1,270 -617	-33%	-$131K	0.39%	88
2022 Q2	$385K	Sell	1,887 -339	-15%	-$69.3K	0.26%	123
2022 Q1	$469K	Buy	2,226 +304	+16%	+$66.1K	0.35%	91
2021 Q4	$461K	Buy	+1,922	New	+$494K	0.49%	49

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Delphia (USA)'s BIIB Position: Q4 2022 in Review

Delphia (USA) sold out of Biogen (BIIB) in Q4 2022, closing a stake of 1,270 shares — an estimated $339K sold.

Delphia (USA) first reported a position in BIIB in Q4 2021 and held it in 4 quarters. The position peaked at $469K in Q1 2022. 1,031 funds tracked by Wall St. Rank hold BIIB as of Q4 2022.

Delphia (USA) reported no remaining Biogen position as of Q4 2022 after selling out during the quarter.
Delphia (USA) sold 1,270 Biogen shares in Q4 2022, an estimated $339K.
Delphia (USA) first reported a position in Biogen in Q4 2021 and held it in 4 quarters.
Delphia (USA)'s Biogen position peaked at $469K in Q1 2022.
1,031 funds tracked by Wall St. Rank held Biogen as of Q4 2022.

Based on Delphia (USA)'s 13F filing for Q4 2022, filed 14 Feb 2023.